Alto Neuroscience to acquire specific clinical-stage assets from Chase Therapeutics for $73.25m.

Alto Neuroscience, a company specializing in precision psychiatry and biomarker-driven treatment development, agreed to acquire a portfolio of dopamine agonist drug combinations from Chase Therapeutics, a company focused on neuropsychiatric and Parkinson’s disease therapies, for $73.25m. “The strategic transaction with Chase Therapeutics allows us to add a major late-stage clinical readout to our pipeline without changing our current cash runway guidance into 2028. Broadly, we believe this opportunity underscores the robust value of our precision platform and bolsters our prospects for long-term growth through driving innovation in psychiatry,” said Amit Etkin, Alto Neuroscience Chief Executive Officer.